PhaseV raises $50M Series A to optimize clinical development
Axios Pro Exclusive ContentIllustration: Allie Carl/AxiosPhaseV, a clinical trial and development software startup, raised a $50 million Series A, CEO Raviv Pryluk tells Axios exclusively.Why it matters: Pharma's need for efficient clinical trials has never been more stark amid FDA upheaval.Pryluk declined to disclose PhaseV's valuation. Follow the money: Accel and Insight Partners led, joined by existing investors Viola Ventures, EXOR and LionBird.PhaseV has ambitious development goals and "wil...
Read more at axios.com